Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities

Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities

Hepatocellular carcinoma (HCC) is the most frequent primitive cancer of the liver, accounting for 90% of all recorded cases. HCC is the third most common cause of cancer-related death, with a 5-year survival rate of just 3%. In the advanced stages, systemic treatments allow doctors to obtain clinica...

Full description

Bibliographic Details
Main Authors: Carmelo Laface, Palma Fedele, Felicia Maria Maselli, Francesca Ambrogio, Caterina Foti, Pasquale Molinari, Michele Ammendola, Marco Lioce, Girolamo Ranieri
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Cancers
Subjects:
hepatocellular carcinoma
cancer therapy
targeted therapy
tyrosine kinase inhibitors
immunotherapy
immune checkpoint inhibitors
Online Access:https://www.mdpi.com/2072-6694/14/16/4028

Internet

https://www.mdpi.com/2072-6694/14/16/4028

Similar Items